How Does Infantile Differ From Juvenile Canavan Disease?

Canavan disease exists on a clinical spectrum. While often described in two main patterns—the severe infantile form (often called classic Canavan disease) and the rarer, milder juvenile form—these are not completely separate categories, and severity can overlap ^[1]. The primary differences lie in symptom severity, how many developmental milestones are achieved, and when symptoms first appear. Estimates suggest 85% to 90% of individuals have the severe, classic pattern, and 10% to 15% have the milder pattern ^[1].

Infantile (Classic/Severe) Presentation

• Onset: Symptoms typically begin very early, between birth and 6 months of age ^[2].
• Developmental Impact: Babies experience severe delays in movement and developmental skills ^[2]. Rather than a sudden loss of all skills, they usually fail to acquire milestones beyond those normally expected in the first year of life (such as head control or sitting), and some may later lose the abilities they did gain ^[2][3].
• Other Symptoms: Common early signs include abnormally large head size (macrocephaly), which usually becomes noticeable between 4 and 18 months, as well as visual impairment ^[2][4]. Seizures may also develop and vary in frequency as a complication ^[2].
• Progression: The classic form involves progressive neurologic challenges that can shorten life expectancy. While it can be fatal in childhood, survival varies considerably with supportive care, and some individuals live into later childhood, adolescence, or adulthood ^[2][5].

Juvenile (Mild) Presentation

• Onset: Mild cases generally present later in childhood, though uncommon cases have begun in infancy (as early as 5 months) but with a much less severe progression ^[6].
• Symptoms: Children with the milder pattern experience less severe symptoms. They may have fine-motor difficulties, differences in muscle tone or coordination, speech delays, learning challenges, or an intention tremor (shaking that happens when reaching for an object) ^[7].
• Progression: They generally have greater functional preservation, achieving more developmental milestones and often maintaining relatively well-preserved cognitive skills ^[6][7]. In some cases, individuals with the mild form have lived into adulthood, attending school and functioning with minimal clinical symptoms ^[7][5].

How Doctors Assess the Trajectory Early On

When a baby is diagnosed with Canavan disease, parents naturally hope for the milder trajectory. Because mild cases can sometimes begin in infancy just like the severe form ^[6], doctors cannot rely on the age of onset alone to predict severity. Instead, they use a combination of tests, though no single test can perfectly forecast a child’s future.

• Biochemical Testing (What it can and cannot tell us): Both forms are caused by a deficiency in the aspartoacylase (ASPA) enzyme, leading to a buildup of a chemical called N-acetylaspartate (NAA) in the brain and urine ^[8][3]. While average urine NAA levels are lower in mild cases than in typical severe cases, individual levels overlap substantially ^[3]. Therefore, urine NAA is primarily a diagnostic tool and not a reliable scale for predicting severity.
• Genetic Testing and Residual Enzyme Activity: Testing the ASPA gene identifies the specific genetic variants a child inherited. Some variants are associated with mild presentations ^[3][8]. In some specialist or research settings, laboratories can assess residual enzyme activity—measuring how much working ASPA enzyme the body might still produce. Higher residual activity often correlates with a milder disease course ^[8]. However, this is not a universally standardized, routine test, and its results should be viewed as a specialist clue rather than a definite prognosis.
• Clinical Monitoring: The most reliable way to understand a child’s trajectory is through close observation by a neurology team. Surprisingly, even unrelated patients with the exact same ASPA genetic mutations do not always share the same severity ^[2], meaning other biological factors play a role.

What This Means for Your Care

You do not need to wait for a “classic” or “mild” label to start helping your child. Treatment and support are guided by your child’s current symptoms and developmental needs, not by a category. Supportive, multidisciplinary care—including physical, occupational, and speech therapy, feeding and swallowing assessments, and vision or seizure monitoring—should begin immediately. Finally, because Canavan disease is genetic, a referral for genetic counseling can help your family understand the test results, testing options for relatives, and what this means for future pregnancies.